Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
Nat Commun. 2020 May 14;11(1):2396. doi: 10.1038/s41467-020-16271-z.
Protein arginine methyltransferases (PRMTs) regulate diverse biological processes and are increasingly being recognized for their potential as drug targets. Here we report the discovery of a potent, selective, and cell-active chemical probe for PRMT7. SGC3027 is a cell permeable prodrug, which in cells is converted to SGC8158, a potent, SAM-competitive PRMT7 inhibitor. Inhibition or knockout of cellular PRMT7 results in drastically reduced levels of arginine monomethylated HSP70 family stress-associated proteins. Structural and biochemical analyses reveal that PRMT7-driven in vitro methylation of HSP70 at R469 requires an ATP-bound, open conformation of HSP70. In cells, SGC3027 inhibits methylation of both constitutive and inducible forms of HSP70, and leads to decreased tolerance for perturbations of proteostasis including heat shock and proteasome inhibitors. These results demonstrate a role for PRMT7 and arginine methylation in stress response.
蛋白质精氨酸甲基转移酶(PRMTs)调节多种生物过程,并且越来越被认为是潜在的药物靶点。在这里,我们报道了一种强效、选择性和细胞活性的 PRMT7 化学探针的发现。SGC3027 是一种细胞通透性前药,在细胞内转化为 SGC8158,这是一种强效的、SAM 竞争性的 PRMT7 抑制剂。细胞中 PRMT7 的抑制或敲除导致精氨酸单甲基化 HSP70 家族应激相关蛋白水平显著降低。结构和生化分析表明,PRMT7 驱动 HSP70 在 R469 处的体外甲基化需要 HSP70 的 ATP 结合、开放构象。在细胞中,SGC3027 抑制 HSP70 的组成型和诱导型形式的甲基化,并导致对包括热休克和蛋白酶体抑制剂在内的蛋白质稳态扰动的耐受性降低。这些结果表明 PRMT7 和精氨酸甲基化在应激反应中起作用。